News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Global CRISPR/Cas9 Market Outlook 2022”, CRISPR/Cas9 technique is being widely accepted by pharmaceutical and biotechnology companies, academic institutes and contract research organizations for various applications. Substantial efforts are being put by players to develop novel technology-based products.
 
Several DNA assembly technologies are available for generating plasmids for biological studies. Many procedures require complex in vitro or in vivo assembly reactions followed by plasmid propagation in recombination. However, the most studied and developed CRISPR/Cas9 system uses CRISPR-associated protein 9 (Cas9) to create a double-stranded DNA break at a specified sequence. For instance, Edit-R Lentiviral Cas9 Nuclease particles are used to facilitate rapid generation of cell lines that constitutively express Cas9 nuclease. Additionally, the CRISPRi (CRISPR interference) has been established for RNA-guided, stable and efficient modulation of transcription of target genes in plants by fusion of inactivated dCas9 to effector domains.
 
Research also showed that dCas9 has been used in functional genetics for regulation of gene expression and novel synthetic biology applications. The study also concluded that owing to the growing demand for CRISPR/Cas9 based products, various venture capitalists are now investing in this market. Geographical analysis also revealed that the CRISPR/Cas9 is more common in North America and Europe, but is expected to administer highest growth rate in Asia Pacific for the next 6 years i.e. 2016-2022.
 
Further adding to the recent developments in the CRISPR/Cas9 industry, researchers concluded that these are unveiling new opportunities for drug target identification and validation, particularly with the application of pooled genetic screening. The study also concluded that CRISPR technology could allow researchers to perform microsurgery on genes, specifically and easily changing a DNA sequence at exact locations on a chromosome. Moreover, the simplicity and robustness of the CRISPR/Cas9 technology will make it possible to respond to newly emerging strains by deploying appropriate sgRNA transgenes into a crop. 
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM864.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm